AQR Capital Management
NRIX icon

AQR Capital Management’s Nurix Therapeutics NRIX Stock Holding History

AQR Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
+16,406
New +$272K ﹤0.01% 3490
2025
Q2 		– Sell
-11,668
Closed -$139K – 3357
2025
Q1 		$139K Sell
11,668
-59,193
-84% -$990K ﹤0.01% 2956
2024
Q4 		$1.34M Buy
70,861
+23,941
+51% +$549K ﹤0.01% 1733
2024
Q3 		$1.05M Buy
46,920
+25,624
+120% +$580K ﹤0.01% 1822
2024
Q2 		$444K Buy
21,296
+9,254
+77% +$144K ﹤0.01% 2098
2024
Q1 		$177K Sell
12,042
-15,414
-56% -$166K ﹤0.01% 2272
2023
Q4 		$283K Buy
+27,456
New +$188K ﹤0.01% 2083

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

AQR Capital Management's NRIX Position: Q1 2026 in Review

AQR Capital Management opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 16,406 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #3490 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in NRIX as recently as Q1 2025.

AQR Capital Management first reported a position in NRIX in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.34M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • AQR Capital Management held 16,406 shares of Nurix Therapeutics worth $254K as of Q1 2026.
  • Nurix Therapeutics was a new AQR Capital Management position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3490 holding.
  • AQR Capital Management first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • AQR Capital Management's Nurix Therapeutics position peaked at $1.34M in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.